Gemfibrozil-d6

Gemfibrozil-d6 is the deuterium labeled Gemfibrozil. Gemfibrozil is an activator of PPAR-α, used as a lipid-lowering agent; Gemfibrozil is also a nonselective inhibitor of several P450 isoforms, with Ki values for CYP2C9, 2C19, 2C8, and 1A2 of 5.8, 24, 69, and 82 μM, respectively.

Product Specifications

CAS Number

[1184986-45-5]

Product Name Alternative

CI-719-d6

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Cytochrome P450; PPAR

Type

Isotope-Labeled Compounds

Related Pathways

Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

Field of Research

Metabolic Disease; Cardiovascular Disease

Purity

98.00

Solubility

10 mM in DMSO

Smiles

OC(C(C([2H])([2H])[2H])(C([2H])([2H])[2H])CCCOC1=C(C=CC(C)=C1)C)=O

Molecular Formula

C15H16D6O3

Molecular Weight

256.37

Precautions

H302, H315, H319, H335

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Pahan K, et al. Gemfibrozil, a lipid-lowering drug, inhibits the induction of nitric-oxide synthase in human astrocytes. J Biol Chem. 2002 Nov 29;277 (48) :45984-91. Epub 2002 Sep 18.|[3]Almad A, et al. The PPAR alpha agonist gemfibrozil is an ineffective treatment for spinal cord injured mice. Exp Neurol. 2011 Dec;232 (2) :309-17.|[4]Wang JS, et al. Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes. Drug Metab Dispos. 2002 Dec;30 (12) :1352-6.